Similarly, no mutations were found in the MAPK, CDK, and PI3K/AKT/mTOR pathways in thyroid tumors and their brain metastases, which would suggest that a therapy targeting these pathways would not be clinically recommended. The gene discussed is AKT1; the disease is thyroid tumor.